Using machine learning methods to predict hepatic encephalopathy in cirrhotic patients with unbalanced data
Hong Yang1, Xinxin Li1, Hongyan Cao1
1Department of Health Statistics, Shanxi Medical University, Taiyuan, China.
Computer Methods and Programs in Biomedicine
|September 23, 2021
Summary
A weighted random forest (WRF) model effectively predicts hepatic encephalopathy (HE) in cirrhosis patients, outperforming traditional methods on unbalanced data. This tool aids clinicians in identifying high-risk individuals for better patient outcomes.
Area of Science:
- Medical informatics
- Machine learning in healthcare
- Cirrhosis research
Background:
- Hepatic encephalopathy (HE) is a frequent complication of cirrhosis.
- Medical data for cirrhosis with HE is often imbalanced, challenging traditional prediction methods.
- Accurate prediction of HE is crucial for managing cirrhosis patients.
Purpose of the Study:
- To develop a machine learning-based risk prediction model for HE in liver cirrhosis patients.
- To improve the efficiency and accuracy of HE prediction using advanced algorithms.
- To address the challenge of unbalanced data in predicting HE.
Main Methods:
- Collected medical data from 1,256 cirrhosis patients, extracting 81 features.
- Compared logistic regression, weighted random forest (WRF), SVM, and weighted SVM (WSVM) for HE prediction.
- Validated the model using an additional 722 cirrhosis patients.
Main Results:
- WRF, WSVM, and logistic regression showed sensitivity > 0.70 for HE recognition.
- Specificity for identifying uncomplicated HE was approximately 85% across models.
- WRF demonstrated superior performance with G-means of 0.82, F-measure of 0.46, and AUC of 0.82.
Conclusions:
- The WRF model is well-suited for classifying unbalanced medical data in HE prediction.
- WRF can be utilized to build a robust risk prediction and evaluation system for cirrhosis with HE.
- Probabilistic WRF models assist clinicians in identifying high-risk HE patients.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
28
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
27
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
27


